Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel RNA-modulating drug candidates. The company's primary focus is on treating rare and ultra-rare genetic diseases caused by nonsense mutations, which are premature stop codons in the genetic code that prevent the production of full-length, functional proteins. Approximately 10% to 15% of patients with individual genetic diseases are believed to have a nonsense mutation as the cause of their condition. Eloxx's proprietary technology platform is centered on Eukaryotic Ribosomal Selective Glycosides (ERSGs). These small molecule drug candidates are designed to promote 'translational read-through' of nonsense mutations, allowing the cellular machinery to bypass the premature stop codon and produce a functional protein. This approach has the potential to treat a wide range of genetic disorders where a single point mutation leads to a truncated protein. The company's lead investigational product candidate is ELX-02, which has been evaluated in clinical trials for the treatment of Cystic Fibrosis (CF) patients with nonsense mutations. Additionally, Eloxx has explored the application of its technology in other indications, such as Alport syndrome, a rare genetic kidney disease. Headquartered in Watertown, Massachusetts, Eloxx Pharmaceuticals aims to address significant unmet medical needs for patients with limited treatment options. The company continues to leverage its expertise in ribosomal RNA and protein synthesis to advance its clinical programs and explore new therapeutic applications for its ERSG library.